HUTCHMED (NASDAQ:HCM) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of HUTCHMED (NASDAQ:HCM) from a buy rating to a hold rating in a report issued on Saturday morning.

Several other brokerages have also recently weighed in on HCM. Jefferies Financial Group raised HUTCHMED to a “strong-buy” rating in a research note on Monday, January 19th. Weiss Ratings reiterated a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $20.88.

HUTCHMED Stock Performance

Shares of NASDAQ:HCM opened at $13.85 on Friday. The company has a current ratio of 4.65, a quick ratio of 4.51 and a debt-to-equity ratio of 0.05. HUTCHMED has a 52 week low of $11.51 and a 52 week high of $19.50. The firm’s fifty day moving average is $14.71 and its 200-day moving average is $14.96.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $2.50 by ($2.49). The company had revenue of $135.42 million during the quarter, compared to analyst estimates of $290.50 million. Research analysts forecast that HUTCHMED will post 0.16 EPS for the current fiscal year.

Institutional Trading of HUTCHMED

Large investors have recently modified their holdings of the stock. State Street Corp increased its stake in shares of HUTCHMED by 1.2% in the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock valued at $4,283,000 after acquiring an additional 3,801 shares in the last quarter. M&G PLC grew its holdings in HUTCHMED by 0.4% in the second quarter. M&G PLC now owns 259,617 shares of the company’s stock worth $3,894,000 after purchasing an additional 924 shares during the period. Amundi increased its stake in HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock valued at $3,620,000 after purchasing an additional 65,898 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of HUTCHMED by 128.0% during the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after purchasing an additional 124,771 shares during the period. Finally, UBS Group AG raised its holdings in shares of HUTCHMED by 112.8% during the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock valued at $2,158,000 after purchasing an additional 72,614 shares during the period. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.